Adaptimmune Therapeutics Plc (ADAPY) Stock Price & Analysis
Adaptimmune Therapeutics Plc (ADAPY) fell 14.71% to USD 0.03 as of July 25, 2026 at 06:12 UTC, according to Nexqual real-time market data.
ADAPY last closed at USD 0.03; the session ranged USD 0.03–0.04 on volume of 61,580 shares. Market capitalization is $7.69M, with a 52-week range of USD 0–0.35 (PNK). Source: Nexqual, July 25, 2026 at 06:12 UTC.
Key Statistics (as of July 25, 2026 at 06:12 UTC)
| Price | USD 0.03 |
|---|---|
| Change | ▼ 14.71% (down) |
| Previous Close | USD 0.03 |
| Open | USD 0.03 |
| Day Range | USD 0.03 – 0.04 |
| 52-Week Range | USD 0 – 0.35 |
| Volume | 61,580 shares |
| Market Cap | $7.69M |
| Exchange | PNK |
Technical Analysis (ADAPY)
Nexqual's technical model rates ADAPY "SELL" based on 2 bullish and 4 bearish signals across 125 daily candles, as of July 25, 2026 at 06:12 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 44.78 (neutral) |
| vs SMA50 | Below (USD 0.03) |
| MACD | 0 (positive) |
Analyst Ratings (ADAPY)
Wall Street analysts rate ADAPY "None", per Nexqual as of July 25, 2026 at 06:12 UTC.
| Consensus Rating | None |
|---|
Earnings (ADAPY)
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2025-06-30 | USD -0.12 vs est -0.13 ▲ beat |
| 2025-03-31 | USD -0.18 vs est -0.17 ▼ miss |
| 2024-12-31 | USD -0.24 vs est -0.15 ▼ miss |
| 2024-09-30 | USD -0.01 vs est -0.18 ▲ beat |
Source: Nexqual, July 25, 2026 at 06:12 UTC.
Financials & Fundamentals (ADAPY)
| Total Revenue | $5.92M |
|---|---|
| Gross Margin | +100.00% |
| Operating Margin | -1082.41% |
| Profit Margin | +425.49% |
| ROE | -346.65% |
| Debt / Equity | 44.05 |
| Current Ratio | 2.04 |
| Total Cash | $25.95M |
| Total Debt | $14.08M |
| Free Cash Flow | $-61.61M |
Source: Nexqual, July 25, 2026 at 06:12 UTC.
Financial Health Score (ADAPY)
Nexqual rates Adaptimmune Therapeutics Plc's overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 06:12 UTC.
| Growth | Strong — Revenue +195% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $26M cash vs $14M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$62M, burning cash |
| Efficiency | Critical — ROE -347%, ROA -25.9% |
Ownership (ADAPY)
| Insider Ownership | +0.63% |
|---|---|
| Institutional Ownership | +0.00% |
| Shares Outstanding | 265.05M |
| Float | 263.34M |
| Short % of Float | +14.34% |
Source: Nexqual, July 25, 2026 at 06:12 UTC.
Leadership (ADAPY)
Adaptimmune Therapeutics Plc is led by Christopher James Hill ACA, BA (Hons) (age 45), CEO, CFO, Secretary & Director, per Nexqual as of July 25, 2026 at 06:12 UTC.
| CEO, CFO, Secretary & Director | Christopher James Hill ACA, BA (Hons) (age 45) |
|---|---|
| Senior Director of Corporate Communications | Dana Lynch |
| Vice President of Commercial Planning | Kimberly Freeman |
| Vice President of Medical Affairs | Laura Gunn |
From Adaptimmune Therapeutics Plc's Latest SEC 10-K Filing (filed 2025-03-24)
Key Strengths & Strategy (as disclosed to the SEC)
- Adaptimmune Therapeutics plc engages in research, development, and subsequent manufacture and commercialisation of cell therapies to treat cancer in the United States and the United Kingdom.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| AFMDQ | Affimed N.V. | USD 0 | ▲ 0% |
| CLLS | Cellectis S.A. | USD 2.84 | ▲ 1.43% |
| ATRA | Atara Biotherapeutics, Inc. | USD 7.9 | ▼ 2.77% |
| MGNX | MacroGenics, Inc. | USD 3.7 | ▼ 13.95% |
| CTMX | CytomX Therapeutics, Inc. | USD 3.24 | ▼ 2.7% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 06:12 UTC. This page is informational and not investment advice.